Nanocell targeting using engineered bispecific antibodies

• Published in: mAbs Vol. 7; no. 1; pp. 53 - 65
• Main Authors: Taylor, Karin, Howard, Christopher B, Jones, Martina L, Sedliarou, Ilya, MacDiarmid, Jennifer, Brahmbhatt, Himanshu, Munro, Trent P, Mahler, Stephen M
• Format: Journal Article
• Language: English
• Published: United States Taylor & Francis 01.01.2015
• Subjects: Animals; Antibodies, Bispecific - chemistry; Antibodies, Bispecific - genetics; Antibodies, Bispecific - immunology; Antibodies, Bispecific - pharmacology; Antibodies, Neoplasm - chemistry; Antibodies, Neoplasm - genetics; Antibodies, Neoplasm - immunology; Antibodies, Neoplasm - pharmacology; Breast Neoplasms - drug therapy; Breast Neoplasms - immunology; CHO Cells; Cricetinae; Cricetulus; Drug Delivery Systems; Female; Humans; Mice; Mice, Nude; Receptor, Epidermal Growth Factor - immunology; Recombinant Proteins - chemistry; Recombinant Proteins - genetics; Recombinant Proteins - immunology; Recombinant Proteins - pharmacology; Single-Chain Antibodies - chemistry; Single-Chain Antibodies - genetics; Single-Chain Antibodies - immunology; Single-Chain Antibodies - pharmacology; Xenograft Model Antitumor Assays; mammalian expression; NP, nanoparticle; mAb, monoclonal antibody; nanoparticle; single chain Fv; BsAb, bispecific antibody; EGFR, epidermal growth factor receptor; IgG, immunoglobulin G; surface plasmon resonance; scFv, single chain variable fragment; bispecific antibody; LPS, lipopolysaccharide; disulfide bridge; tumor regression; EDVTM, EnGeneIC Delivery Vehicle

There are many design formats for bispecific antibodies (BsAbs), and the best design choice is highly dependent on the final application. Our aim was to engineer BsAbs to target a novel nanocell (EnGeneIC Delivery Vehicle or EDV(TM)nanocell) to the epidermal growth factor receptor (EGFR). EDV(TM)nan...